drugset / Trial / NCT02217618

A Study of LY2409021 in Healthy Participants

NCT02217618

Phase 1 Completed 16 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelBasic science

Summary

The study involves a single dose of LY2409021 taken by mouth. The purpose of this study is to determine how much LY2409021 enters the bloodstream and how long the body takes to get rid of the drug after the dose. This study will last approximately 28 days, not including screening. Screening can occur within 30 days prior to the start of the study.

Timeline

Start
2014-08
Primary completion
2014-09
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject ADOMEGLIVANT Small molecule 20 mg Oral

Indications

No indication recorded.